KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

BioNTech SE (BNTX) Shares Outstanding (Weighted Average) (2018 - 2025)

BioNTech SE's Shares Outstanding (Weighted Average) history spans 8 years, with the latest figure at $301.5 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 26123433.74% to $301.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $301.5 million, a 26123433.74% increase, with the full-year FY2025 number at $292.6 million, up 25355189.87% from a year prior.
  • Shares Outstanding (Weighted Average) hit $301.5 million in Q4 2025 for BioNTech SE, up from $290.6 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for BNTX hit a ceiling of $301.5 million in Q4 2025 and a floor of $900.54 in Q3 2024.
  • Historically, Shares Outstanding (Weighted Average) has averaged $214.0 million across 5 years, with a median of $267.3 million in 2024.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): tumbled 100.0% in 2024 and later surged 32272436.28% in 2025.
  • Tracing BNTX's Shares Outstanding (Weighted Average) over 5 years: stood at $279.1 million in 2021, then decreased by 11.07% to $248.2 million in 2022, then increased by 4.29% to $258.9 million in 2023, then tumbled by 100.0% to $1154.1 in 2024, then soared by 26123433.74% to $301.5 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for BNTX at $301.5 million in Q4 2025, $290.6 million in Q3 2025, and $281.4 million in Q2 2025.